⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10818636 | 1.00 | — | — | |
| SCHEMBL11347194 | 1.00 | — | — | |
| Water SCHEMBL15557231 | 1.00 | — | — | |
| SCHEMBL8118702 | 1.00 | — | — | |
| Water SCHEMBL526974 | 0.71 | — | — | |
| Fluoride Ion SCHEMBL3793240 | 0.71 | CA4 (0.50) | — | |
| Hydrogen Sulfide SCHEMBL8909006 | 0.71 | — | — | |
| Iodide SCHEMBL330012 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL14691308 | 0.71 | — | — | |
| SCHEMBL4855730 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069726-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | UNIV SASKATCHEWAN (CA) | 2026-03-12 | — | — | US | claimed |
| US-12479792-B2 | Compositions of chelating molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-25 | — | — | US | claimed |
| EP-3503930-B1 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | FRED HUTCHINSON CANCER CENTER (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2023235985-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2023-12-14 | — | — | WO | claimed |
| US-20220160904-A1 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-26 | — | — | US | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-20260069726-A1 | ZWITTERIONIC COMPOUNDS AND USES THEREOF | UNIV SASKATCHEWAN (CA) | 2026-03-12 | — | — | US | disclosed |
| EP-4702044-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-12479792-B2 | Compositions of chelating molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-3520117-B1 | SEPARATION OF METAL IONS BY LIQUID-LIQUID EXTRACTION | UNIV CALIFORNIA (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023158802-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| US-20220160904-A1 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| CN-216311353-U | Molten salt fast reactor | 中国科学院上海应用物理研究所 | 2022-04-15 | — | — | CN | disclosed |
| US-20220106623-A1 | SPATIAL MAPPING OF CELLS AND CELL TYPES IN COMPLEX TISSUES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114093529-A | Molten salt fast reactor | 中国科学院上海应用物理研究所 | 2022-02-25 | — | — | CN | disclosed |